Metro (MRU)
Q4 FY2026 earnings · · Past
Actual event
Metro's Q4 sales rose 1.4%; food same-store sales fell 1.9% while pharmacy grew 5.5%. Adjusted diluted EPS was C$0.97; Metro estimates the Laval labour conflict cost C$0.16/share, still included in adjusted EPS. Our central value falls from a reconstructed C$95.40 reference to C$91.96.
Released Vancouver time
Unscored · No forecast was locked
Issuer releaseResearch work
Analysis published
Published
Published MRU report: bear C$76.16 (C$4.48 × 17), central C$91.96 (C$4.84 × 19), bull C$107.10 (C$5.10 × 21). Against the November 18 C$97.58 close, central value is 5.8% lower before dividends. These are analyst sensitivities. The C$95.40 starting point is reconstructed, not a previously published Peralta valuation.
Read the equity report →Trade decision
Watch
The reconstructed pre-results reference is FY2025 adjusted EPS of C$4.77 at 20×, or C$95.40; no earlier Peralta MRU valuation was published. FY2026 adjusted EPS of C$4.48 still includes Metro's estimated C$0.48/share Laval cost. Crediting 75% recovery gives illustrative FY2027 earnings power of C$4.84. At the old 20× multiple that raises value C$1.40/share, but a 19× multiple for weak food comps and cash conversion subtracts C$4.84. Net central revision: minus C$3.44/share, or 3.6%.
Revisit Check next-quarter food same-store sales, gross margin and recurring cash after leases. Sustained improvement would raise the recovery fraction or multiple; persistent weakness would lower them.
Preview
Metro will release fourth-quarter results on November 18, followed by a 9:00 a.m. ET call.
Review plan
Review food and pharmacy same-store sales, gross margin and working-capital conversion.
Price impact
Separate unit and traffic growth from inflation and changes in pharmacy mix.